Betaxolol

證據等級: L5

預測適應症: 1 個

Betaxolol: From Glaucoma to Primary Hereditary Glaucoma

One-Sentence Summary

Betaxolol is a selective β1-adrenergic receptor antagonist traditionally used for open-angle glaucoma and ocular hypertension management by reducing aqueous humor production. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma (including primary congenital glaucoma and juvenile open-angle glaucoma), with no clinical trials and no publications specifically supporting this direction — evidence is currently model-prediction only.

Quick Overview

Item	Content
Original Indication	Glaucoma / Ocular Hypertension (selective β1-blocker, ophthalmic use)
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.74%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Betaxolol is a cardioselective β1-adrenergic receptor antagonist. When applied topically to the eye, it acts on the ciliary body epithelium to suppress cAMP-dependent aqueous humor secretion, thereby lowering intraocular pressure (IOP). This mechanism is well-established for open-angle glaucoma and ocular hypertension, and represents the pharmacological rationale underlying the TxGNN model’s prediction.

Primary hereditary glaucoma — encompassing primary congenital glaucoma (PCG) and juvenile open-angle glaucoma (JOAG) — is pathophysiologically distinct from adult open-angle glaucoma. The defining lesion is a developmental abnormality of the trabecular meshwork and anterior chamber angle, leading to impaired aqueous outflow rather than overproduction. Betaxolol’s mechanism targets the production side of the IOP equation, offering a theoretical compensatory role when outflow is structurally compromised.

However, the mechanistic link is of moderate rather than strong plausibility. The first-line treatment for PCG is surgical (goniotomy or trabeculotomy), with pharmacotherapy reserved for pre-operative stabilisation or adjunctive use. Critically, genetic subtypes of hereditary glaucoma (e.g., CYP1B1, MYOC mutations) introduce variable trabecular biology that may substantially alter beta-blocker responsiveness — and no direct genotype-stratified data currently exist to quantify this effect.

Clinical Trial Evidence

Currently no related clinical trials registered for Betaxolol in Primary Hereditary Glaucoma.

Literature Evidence

Currently no related literature available for Betaxolol specifically in Primary Hereditary Glaucoma.

India Market Information

Betaxolol has no registered products in India (0 authorisations on record). The drug is currently classified as Not Marketed in the Indian regulatory database.

Safety Considerations

Drug Interactions: Betaxolol has 173 documented interactions in the DDInter database. Key moderate-level interactions include:

Interacting Drug	Severity	Clinical Note
Epinephrine	Moderate	Risk of hypertensive response followed by bradycardia; caution in ophthalmic emergency settings
Hydrocortisone / Dexamethasone / Betamethasone / Triamcinolone / Budesonide	Moderate	Corticosteroids may attenuate antihypertensive effect and elevate IOP — clinically relevant in glaucoma management
Calcium salts (acetate, carbonate, citrate, gluconate, lactate, glubionate)	Moderate	May affect beta-blocker absorption or cardiovascular response
Bupropion	Moderate	Potential for pharmacodynamic interaction affecting heart rate and blood pressure
Atropine / Hyoscyamine	Moderate	Anticholinergic agents may counteract beta-blocker-mediated bradycardia
Morphine	Moderate	Additive hypotensive and cardiodepressant effects
Acetohexamide	Moderate	Beta-blockers may mask hypoglycaemia symptoms
Acetylsalicylic acid	Minor	Possible modest attenuation of antihypertensive effect
Aluminium hydroxide / Attapulgite	Minor	May reduce oral betaxolol absorption if given simultaneously

Note: Formal warnings and contraindications (CDSCO/package insert) are not available in the current evidence pack. Please refer to the manufacturer’s prescribing information for complete safety guidance.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high prediction score (99.74%), and the proposed mechanism — IOP reduction via β1-receptor blockade — is biologically coherent. However, there is currently zero clinical trial or published literature evidence specifically linking Betaxolol to Primary Hereditary Glaucoma, the disease has a structurally distinct pathophysiology from typical open-angle glaucoma, and the drug is not registered in India. This does not meet the minimum evidence threshold to proceed.

To advance beyond Hold, the following is needed:

MOA confirmation: Retrieve DrugBank full mechanism-of-action data to formally document the ciliary body IOP-lowering pathway (Data Gap DG002)
Safety dossier: Obtain and parse the CDSCO/package insert PDF for complete warnings and contraindications (Data Gap DG001)
Targeted literature search: Expand PubMed query to include broader terms (e.g., “betaxolol AND congenital glaucoma”, “beta-blocker AND CYP1B1 glaucoma”, “beta-blocker AND pediatric glaucoma”) to determine if any evidence exists under adjacent search terms
Regulatory pathway assessment: Evaluate CDSCO orphan drug designation eligibility for primary congenital glaucoma
Genotype-stratification consideration: Assess whether CYP1B1 or MYOC mutational status would moderate beta-blocker responsiveness before any translational study design
Surgical standard-of-care alignment: Define the proposed clinical role (pre-operative IOP control vs. long-term adjunct) to frame a realistic feasibility hypothesis

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.